Terms ending in 2037
Every in-force patent on Tesaro, Inc.'s record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,383,542 | Methods of Treating Ovarian Cancer In force · High confidence | Tesaro, Inc. | In force | High confidence | |
| US 12,527,780 | Methods of Treating Ovarian Cancer In force · High confidence | Tesaro, Inc. | In force | High confidence | |
| US 11,753,472 | Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3) In force · High confidence | Tesaro, Inc. | In force | High confidence |
3 of 3 patents shown. Soonest term end first, then patent number.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.